ATE315643T1 - Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung - Google Patents

Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung

Info

Publication number
ATE315643T1
ATE315643T1 AT95904808T AT95904808T ATE315643T1 AT E315643 T1 ATE315643 T1 AT E315643T1 AT 95904808 T AT95904808 T AT 95904808T AT 95904808 T AT95904808 T AT 95904808T AT E315643 T1 ATE315643 T1 AT E315643T1
Authority
AT
Austria
Prior art keywords
methods
cdn
dna encoding
modulating proteins
apoptosis modulating
Prior art date
Application number
AT95904808T
Other languages
English (en)
Inventor
Michael C Kiefer
Philip J Barr
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Application granted granted Critical
Publication of ATE315643T1 publication Critical patent/ATE315643T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
AT95904808T 1993-11-30 1994-11-30 Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung ATE315643T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16006793A 1993-11-30 1993-11-30
US32015794A 1994-10-07 1994-10-07

Publications (1)

Publication Number Publication Date
ATE315643T1 true ATE315643T1 (de) 2006-02-15

Family

ID=26856568

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95904808T ATE315643T1 (de) 1993-11-30 1994-11-30 Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung

Country Status (14)

Country Link
US (7) US6015687A (de)
EP (1) EP0731636B1 (de)
JP (4) JP4129055B2 (de)
CN (1) CN1139871A (de)
AT (1) ATE315643T1 (de)
AU (1) AU688839B2 (de)
CA (1) CA2177827C (de)
DE (1) DE69434614T2 (de)
ES (1) ES2256843T3 (de)
FI (1) FI962247A (de)
HU (1) HUT74276A (de)
NO (1) NO962188L (de)
NZ (1) NZ277946A (de)
WO (1) WO1995015084A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688839B2 (en) 1993-11-30 1998-03-19 Tanox, Inc. Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
JPH1189573A (ja) * 1994-10-14 1999-04-06 Yutaka Shindo アポトーシス関与遺伝子
CA2216856C (en) * 1995-04-20 2008-02-19 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apoptosis-modulating proteins
US6436639B1 (en) * 1997-02-18 2002-08-20 Tanox, Inc. Bak promoter expression system
WO1998041626A1 (en) 1997-03-20 1998-09-24 Lxr Biotechnology Inc. A NOVEL Bak BINDING PROTEIN, DNA ENCODING THE PROTEIN, AND METHODS OF USE THEREOF
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6218144B1 (en) * 1997-06-30 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Costal2 genes and their uses
US6641998B2 (en) * 1997-10-10 2003-11-04 Stratagene Methods and kits to enrich for desired nucleic acid sequences
AU6162999A (en) * 1998-09-24 2000-04-10 Promega Corporation Apoptosis marker antibodies and methods of use
CA2363621A1 (en) 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
AU2001231009A1 (en) 2000-01-21 2001-07-31 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
WO2002006479A2 (de) * 2000-07-14 2002-01-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Apoptose-induzierende dna-sequenzen
CA2439532A1 (en) * 2001-03-02 2002-09-26 Mds Proteomics Inc. Methods and reagents for regulating apoptosis
EP1253200A1 (de) * 2001-04-25 2002-10-30 Société des Produits Nestlé S.A. Kakao-Polypeptide und ihre Anwendung zur Herstellung von Kakao- und Schokoladenaroma
PT1432450E (pt) * 2001-10-03 2006-05-31 Bioniche Life Sciences Inc Trietilenoglicol-colesteril-oligonucleotidos terapeuticamente uteis
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
US20060252922A1 (en) * 2002-12-04 2006-11-09 Macina Roberto A Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004072225A2 (en) * 2003-02-12 2004-08-26 Ramot At Tel Aviv University Ltd. Transgenic fungi expressing bcl-2 and methods of using bcl-2 or portions thereof for improving biomass production, survival, longevity, stress resistance and pathogenicity of fungi
US7368428B2 (en) * 2003-06-23 2008-05-06 A&G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
EP1660010B1 (de) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Zusammensetzungen und verfahren zur wiederherstellung der empfänglichkeit für eine behandlung mit her2-antagonisten
PT2500360E (pt) * 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
WO2011056886A2 (en) * 2009-11-03 2011-05-12 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
EP2418286A1 (de) * 2010-08-10 2012-02-15 QIAGEN GmbH Verbessertes Verfahren zur isothermalen Amplifikation von Nukleinsäuren
US20130166458A1 (en) * 2011-12-22 2013-06-27 Embraer S.A. System and method for remote and automatic assessment of structural damage and repair
US20230392166A1 (en) * 2020-10-21 2023-12-07 Wisconsin Alumni Research Foundation Anti-apoptotic vector and method of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5395767A (en) 1992-06-22 1995-03-07 Regents Of The University Of California Gene for ataxia-telangiectasia complementation group D (ATDC)
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
EP0711174A4 (de) * 1993-06-24 1997-11-12 Gen Hospital Corp Gene für den programmierten zelltod und proteine
WO1995005738A1 (en) * 1993-08-20 1995-03-02 Massachusetts Institute Of Technology Anticancer agents and apoptosis
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
AU688839B2 (en) * 1993-11-30 1998-03-19 Tanox, Inc. Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof
US5672686A (en) * 1994-08-09 1997-09-30 Immunogen, Inc. Bcl-Y - specific antibodies
CA2216856C (en) * 1995-04-20 2008-02-19 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apoptosis-modulating proteins
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7

Also Published As

Publication number Publication date
JP2009189377A (ja) 2009-08-27
AU1335195A (en) 1995-06-19
FI962247A (fi) 1996-07-22
US20050164284A1 (en) 2005-07-28
US20070117748A1 (en) 2007-05-24
EP0731636B1 (de) 2006-01-11
AU688839B2 (en) 1998-03-19
JP4129055B2 (ja) 2008-07-30
HUT74276A (en) 1996-11-28
WO1995015084A1 (en) 1995-06-08
HU9601448D0 (en) 1996-07-29
US6586395B1 (en) 2003-07-01
JP2006061159A (ja) 2006-03-09
CA2177827A1 (en) 1995-06-08
CA2177827C (en) 2007-08-28
DE69434614D1 (de) 2006-04-06
US6015687A (en) 2000-01-18
US5770443A (en) 1998-06-23
EP0731636A1 (de) 1996-09-18
CN1139871A (zh) 1997-01-08
JPH09509567A (ja) 1997-09-30
FI962247A0 (fi) 1996-05-29
NZ277946A (en) 1998-03-25
EP0731636A4 (de) 1998-04-15
US6903195B1 (en) 2005-06-07
NO962188L (no) 1996-07-23
US7108989B2 (en) 2006-09-19
US20030008837A1 (en) 2003-01-09
JP2007252391A (ja) 2007-10-04
ES2256843T3 (es) 2006-07-16
NO962188D0 (no) 1996-05-29
DE69434614T2 (de) 2006-10-05
US7754418B2 (en) 2010-07-13

Similar Documents

Publication Publication Date Title
ATE315643T1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
DK0652960T3 (da) Cyklisk GMP-bindende, cyklisk GMP-specifikke phosphodiesterasematerialer og fremgangsmåder
AU7301898A (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
ATE320500T1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
DE69738586D1 (de) Hohe expressionsrate von proteinen
LV11486A (lv) Fermenti DNS sekvenesanai
EP0892048A3 (de) XAF Gene und Polypeptide und deren Verwendung zur Modulation der Apoptose
HUP9904414A2 (hu) A neuritin neurogén
ATE314477T1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
DK0719328T3 (da) Genet GRB 3-3, varianter deraf og anvendelse deraf
DE69534471D1 (de) Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
AU1614997A (en) Use of neuronal apoptosis inhibitor protein (naip)
ZA97835B (en) Purified sr-p70 protein
DE69838810D1 (de) Gen von alteromonas
EA199900893A1 (ru) Бактериальные плазмиды
DK43393D0 (da) Dna-sekvens, der koder for et enzym
BR9914090A (pt) ácidos nucléicos codificando uma sub-unidade gama da proteìna g envolvida em transdução sensorial
ATE104344T1 (de) Gereinigte ubiquitin-hydrolase, diese kodierende dns-sequenzen und ihre verwendung zur gewinnung von polypeptiden.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties